83-2271-31　［受注停止］KRIBIOLISA Lixisenatide ELISA 1 x 96 wells　KBI5021

特徴

• Description：Immunoassay for quantitative estimation of Lixisenatide in human serum, plasma and tissue extracts.
• Lixisenatide （Lyxumia） is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 （GLP-1） which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The Lixisenatide ELISA is a competitive immunoassay for the determination of Lixisenatide.
• The antiserum is captured by antibodies coated on a 96-well plate.
• A constant concentration of Biotin Concentrate and varying concentrations of unlabeled standard or sample compete for binding specifically to the antiserum.
• Captured
• Bt-tracer is subsequently bound by SA-HRP （streptavidin-conjugated horseradish peroxidase）, which produces a soluble colored product after a substrate is added.
• The enzyme reaction is stopped by dispensing an acidic solution （H2SO4） into the wells after 10 min at room temperature turning the solution from blue to yellow.
• The optical density （OD） of the solution at 450 nm is inversely proportional to the amount of specific Lixisenatide bound.